2012 News Releases

Filter by Year

2012 News Releases

Previous | Next

December 18, 2012 Teva Calls 1.700% Senior Notes Due 2014 for Redemption

- Closes $2 Billion Senior Note Offering - JERUSALEM--(BUSINESS WIRE)--Dec. 18, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that its finance subsidiary Teva Pharmaceutical Finance IV, LLC has called for redemption its $1 billion outstanding principal amount of 1.700% senior notes due 2014 (CUSIP No. 88166H AA5). The redemption is being funded with proceeds from Teva’s offering of $2 billion principal amount   Read More »

December 18, 2012 Teva Signs New $3.0 Billion Syndicated Revolving Credit Facility

New Facility to Replace Existing $2.5 Billion Facility Secures Teva's Liquidity through Revolving Credit Lines JERUSALEM--(BUSINESS WIRE)--Dec. 18, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has entered into a new five-year, $3.0 billion unsecured revolving credit facility, which replaces its existing $2.5 billion credit facility. “By signing this new revolving credit facility, with its increased size and extended term, we took another step on our recen  Read More »

December 16, 2012 Teva Enters Agreement with Handok to Establish Business Venture with Significant Presence in Korean Pharmaceutical Market

- First commercial deal for Teva in East Asian territory outside Japan - - Pharmaceutical market in South Korea worth USD 14 billion – JERUSALEM & SEOUL, Korea--(BUSINESS WIRE)--Dec. 16, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Handok Pharmaceuticals Co., Ltd. (KRX: 002390) announced today their agreement to establish a business venture in South Korea, allowing Teva to gain entrance into the Korean pharmaceutical market, currently valued at approximately USD 14 billio  Read More »

December 13, 2012 Teva Announces Pricing of $2.0 Billion of Senior Notes

- Proceeds to be used for repayment of existing debt - JERUSALEM--(BUSINESS WIRE)--Dec. 13, 2012-- Teva Pharmaceutical Industries Limited (NYSE: TEVA) announced today that it successfully priced a debt offering by its special purpose finance subsidiaries, consisting of two tranches: $700,000,000 of 2.250% fixed rate senior notes maturing in March 2020 issued by Teva Pharmaceutical Finance IV, LLC; and $1,300,000,000 of 2.950% fixed rate senior notes maturing in December 2022 issued by Te  Read More »

December 13, 2012 Teva Receives A- Rating from Fitch Ratings with a Stable Outlook

JERUSALEM--(BUSINESS WIRE)--Dec. 13, 2012-- Teva Pharmaceutical Industries Limited (NYSE: TEVA) announced today that Fitch Ratings have assigned to it an initial long term issuer rating of A-, with a stable outlook. The credit rating agency said that the rating reflects Teva’s strategic position as the world's largest generic drug manufacturer, financial discipline, strong cash flow and liquidity, and capital deployment toward debt red  Read More »

December 11, 2012 Teva and Xenon Announce Teva’s World Wide License of Xenon’s Pain Drug XEN402

XEN402 is a Strategic Fit for Teva’s Commercial, R&D and Technology focus in CNS and Pain JERUSALEM & BURNABY, British Columbia--(BUSINESS WIRE)--Dec. 11, 2012-- Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that they have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is currently in clinical development for a variety of painful disorders. This product specifically targets sodium chan  Read More »

December 06, 2012 Teva Invites the Public to Listen to Its 2012 Investor Meeting Webcast

JERUSALEM--(BUSINESS WIRE)--Dec. 6, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) invites investors and the general public to listen to a live audio webcast of its 2012 Investor Meeting on Tuesday, December 11, 2012 at 12:00 p.m. ET.     What: Teva’s 2012 Investor Meeting   Who: Teva Management   When: Tuesday, December 11, 2012 at 12:00 p.m. ET   Where: www.tevapharm.  Read More »

November 30, 2012 Teva Provides 2013 Non-GAAP Financial Outlook

2013 Non-GAAP Diluted EPS of $4.85 to $5.15 JERUSALEM--(BUSINESS WIRE)--Nov. 30, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) provided its current outlook for non-GAAP financial performance for the full year ending December 31, 2013. Financial Targets: Total net revenues of between $19.5-$20.5 billion, consisting of:   Region   Net Revenues United States   $10.0 to $10.6B Europe   $5.5 to $6.1B Rest of World   $3  Read More »

November 29, 2012 Teva to Host Conference Call and Webcast on November 30, 2012

JERUSALEM--(BUSINESS WIRE)--Nov. 29, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will host a conference call and live webcast on Friday, November 30, 2012 at 8:00 a.m. ET to communicate its 2013 business outlook. A Question & Answer session will follow. A live webcast of the call will be available on Teva's website at: http://www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.   Read More »

November 09, 2012 Phase III Data for Teva’s QNASL® (beclomethasone dipropionate) Demonstrate Efficacy Profile in Pediatric Patients with Seasonal Allergic Rhinitis

Additional Phase III Data Show Long-Term Ocular Safety Profile and Support Device Functionality and Reliability JERUSALEM--(BUSINESS WIRE)--Nov. 9, 2012-- Teva Pharmaceutical Industries Ltd. announced today additional data from the Phase III clinical program for QNASL® (beclomethasone dipropionate) Nasal Aerosol, highlighting the drug’s efficacy profile in treating children (ages 6-11) with nasal symptoms of seasonal allergic rhinitis (SAR). QNASL® is a nonaqueous, “dry” nasal aerosol corticos  Read More »

November 05, 2012 Teva Announces Changes to Executive Leadership Team

Allan Oberman Named President and CEO Teva Americas Generics Jill DeSimone joins Teva as SVP and GM of Teva Global Women’s Health William S. Marth to Retire as President & CEO of Teva Americas JERUSALEM--(BUSINESS WIRE)--Nov. 5, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced management changes to its executive leadership team. Mr. Allan Oberman, Senior Vice President of North America Generic Pharmaceuticals of Teva, has been appointed President and Chief Ex  Read More »

November 01, 2012 Teva Reports Third Quarter 2012 Results

Click here for Webcast Net Revenues Total $5.0 Billion, up 14% Non-GAAP EPS of $1.28, up 2% JERUSALEM--(BUSINESS WIRE)--Nov. 1, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended September 30, 2012. Highlights: Net revenues of $5.0 billion, compared to $4.3 billion in the third quarter of 2011, an increase of 14%. Net revenues organic growth of 1.3% compared to the third quarter of 2011, and 6% organic growth excluding the effect of   Read More »

October 26, 2012 Teva Receives Approval For SYNRIBOTM (Omacetaxine Mepesuccinate) for Injection

Treats Chronic Myeloid Leukemia (CML) in Patients Who Have Become Resistant to or Intolerant of Two of More Tyrosine Kinase Inhibitors Protein Synthesis Inhibitor Provides New Treatment Option for CML Patients who Fail Prior TKI Therapy JERUSALEM--(BUSINESS WIRE)--Oct. 26, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) approved SYNRIBO (omacetaxine mepesu  Read More »

October 22, 2012 Phase IIa Laquinimod Trial Results Show Positive Data for Potential Use in Active Crohn's Disease

Newly Presented Data at 20th United European Gastroenterology (UEG) Week Conference Show Significant Impact of Laquinimod on Clinical Remission versus Placebo JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Oct. 22, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced the presentation of Phase IIa clinical data for investigational laquinimod in moderate to severe Crohn’s diseas  Read More »

October 17, 2012 Teva to Report Third Quarter 2012 Financial Results on November 1, 2012

JERUSALEM, Israel--(BUSINESS WIRE)--Oct. 17, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its third quarter 2012 financial results on Thursday, November 1, 2012 at 7:00 a.m. EDT. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. EDT to discuss its third quarter 2012 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the followi  Read More »

October 10, 2012 Teva to Present Positive Data for Glatiramer Acetate 40 mg/1 ml Given Three Times Weekly for Relapsing-Remitting Multiple Sclerosis

- Glatiramer acetate (GA) 40 mg/1 ml three times weekly significantly reduced annualized relapse rates (ARR) - Significant reductions in new/enlarging T2 and gadolinium-enhancing (GdE) lesions in RRMS patients also observed - New data being presented at late-breaking news session at the 28th ECTRIMS congress JERUSALEM--(BUSINESS WIRE)--Oct. 10, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced data   Read More »

October 08, 2012 New Data Presented at the 28th ECTRIMS Congress Showcase Teva’s Ongoing Commitment to Multiple Sclerosis Research

Highlights Include Late-Breaking Presentation of the Phase III GALA Results Evaluating Glatiramer Acetate 40 mg/1 ml JERUSALEM--(BUSINESS WIRE)--Oct. 8, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that key data from the Company’s multiple sclerosis (MS) franchise will be featured at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13, 2012. Data presentations will provide new insights   Read More »

September 27, 2012 Teva Expands Central Nervous System (CNS) Development Pipeline with Acquisition of Huntexil® Development Program Rights from NeuroSearch A/S

Drug candidate to be assessed for managing voluntary motor disturbances in Huntington disease JERUSALEM--(BUSINESS WIRE)--Sep. 27, 2012-- Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced today that it has concluded an Asset Transfer Agreement with NeuroSearch A/S of Denmark (OMX: NEUR) to purchase all rights, assets and obligations relating to Huntexil® (pridopidine / ACR16), a drug candidate being developed for the symptomati  Read More »

September 14, 2012 Bayer HealthCare to acquire U.S. animal health business from Teva Pharmaceutical Industries

Enables Bayer HealthCare to expand companion animal and food animal product lines in the United States Transaction reflects Teva's commitment to human healthcare, in alignment with its strategy to focus on its core business assets SHAWNEE, Kan. and JERUSALEM, Sept. 14, 2012 /PRNewswire/ -- Bayer HealthCare LLC and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that they have signed an agreement in which Bayer will acquire the U.S. based animal health business of T  Read More »

September 13, 2012 Teva Pharmaceutical Announces the Appointment of Professor Itzhak Krinsky as Chairman of Teva Japan and Teva South Korea and Head of Business Development in Asia-Pacific

- Appointment Aims to Further Strengthen Teva's Management Team and Commitment to the Asia-Pacific Region - JERUSALEM--(BUSINESS WIRE)--Sep. 13, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the appointment of Professor Itzhak Krinsky as Chairman of Teva Japan and Teva South Korea and Head of Business Development Asia-Pacific. Currently serving as Executive Vice President, Corporate Business Development at Teva, Professor Krinsky's new appointment will be effective mi  Read More »

August 30, 2012 Teva Announces FDA Grants Approval for Tbo-filgrastim for the Treatment of Chemotherapy-Induced Neutropenia

First New Treatment for Neutropenia Approved in the United States in 10 Years Marks First Supportive Care Therapy for Cancer Patients from Teva Oncology JERUSALEM--(BUSINESS WIRE)--Aug. 30, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for tbo-filgrastim (XM02 filgrastim), the first new granulocyte colony-stimulating factor (G-CSF) to be approved in the United States in more than 10 years. Tbo-filg  Read More »

August 17, 2012 Teva Announces Launch of Generic ACTOplus met® in the United States

JERUSALEM--(BUSINESS WIRE)--Aug. 17, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of an authorized generic of ACTOplus met® (pioglitazone/metformin tablets)15 mg/500 mg, 15 mg/850 mg. ACTOplus met® is marketed by Takeda Pharmaceuticals U.S.A., Inc. and used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOplus met® had annual sales of approximately $413 million in the United States, based on IMS sales data a  Read More »

August 17, 2012 Teva Announces Launch of Generic Actos® in the United States

JERUSALEM--(BUSINESS WIRE)--Aug. 17, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of an authorized generic of Actos® (pioglitazone-hydrochloride tablets) 15, 30 and 45mg. Actos® is marketed by Takeda Pharmaceuticals U.S.A., Inc. and used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. The brand product had annual sales of approximately $2.7 billion in the United States, based on IMS sales data as of June 30, 20  Read More »

August 08, 2012 Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis

The clinical trial protocol has been granted a Special Protocol Assessment agreement by the Food and Drug Administration JERUSALEM, Israel & LUND, Sweden--(BUSINESS WIRE)--Aug. 8, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS). The companies are to initiate a third Phase III study   Read More »

August 02, 2012 Teva Pharmaceutical Announces New Appointments of President and Chief Executive Officer, Global Operations and Executive Vice President, Community and Institutional Affairs

JERUSALEM--(BUSINESS WIRE)--Aug. 2, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the appointments of Dr. Carlo De Notaristefani as President and Chief Executive Officer of Global Operations, and Mr. Aharon (Arik) Yaari as the Executive Vice President to the newly created organization, Community and Institutional Affairs. Both Dr. De Notaristefani and Mr. Yaari will report directly to Dr. Jeremy Levin, President and Chief Executive Officer of Teva Pharmaceutical Industr  Read More »

August 02, 2012 Teva Reports Second Quarter 2012 Results

Click here for Webcast Net Revenues Total $5.0 Billion, up 19% GAAP EPS of $0.99, up 55%; Non-GAAP EPS of $1.28, up 16% JERUSALEM--(BUSINESS WIRE)--Aug. 2, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended June 30, 2012. Highlights: Net revenues of $5.0 billion, compared to $4.2 billion in the second quarter of 2011, an increase of 19%. Net revenues organic growth of 3% compared to the second quarter of 2011, and 7% excluding the ef  Read More »

July 13, 2012 Teva to Report Second Quarter 2012 Financial Results on August 2, 2012

JERUSALEM, Israel--(BUSINESS WIRE)--Jul. 13, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its second quarter 2012 financial results on Thursday, August 2, 2012 at 7:00 a.m. EDT. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. EDT to discuss its second quarter 2012 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the followi  Read More »

July 11, 2012 Teva Announces Favorable United Kingdom Court Ruling In COPAXONE® Patent Litigation Proceeding

JERUSALEM--(BUSINESS WIRE)--Jul. 11, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that the United Kingdom High Court of Justice issued a decision in favor of Teva in a patent litigation proceeding against Generics (UK) Limited, a subsidiary of Mylan Laboratories Inc., on July 11, 2012. Generics (UK) Limited commenced the proceeding in the UK to seek the revocation of European Patent (UK) 762,888, a patent for COPAXONE® (glatiramer acetate injection) expiring May 23, 2015, an  Read More »

June 29, 2012 Teva Announces Progress of Biologic Investigational Drugs Evaluated to Treat Neutropenia in Breast Cancer Patients Undergoing Chemotherapy

- Clinical Results for Lipegfilgrastim and Balugrastim Highlighted at Oncology Conference; Teva Committed to Further Advancing Its Biologic Oncology Programs - JERUSALEM--(BUSINESS WIRE)--Jun. 29, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the presentation of clinical results for its biologic oncology candidates, lipegfilgrastim and balugrastim, at the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) 201  Read More »

June 23, 2012 Teva Announces Favorable Court Ruling in COPAXONE® Patent Infringement Litigation

JERUSALEM--(BUSINESS WIRE)--Jun. 23, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the U.S. District Court for the Southern District of New York has found in favor of Teva in the Company's patent infringement lawsuit against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Laboratories Inc./Natco Pharmaceuticals regarding Teva's relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE®. Teva filed suit against Momenta/Sandoz and Mylan/Natco for infringement of  Read More »

June 21, 2012 Teva Announces Launch of Generic Symbyax® in the United States

JERUSALEM--(BUSINESS WIRE)--Jun. 21, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company’s generic equivalent of Symbyax®. Symbyax® is marketed by Lilly USA and approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults. The brand product had annual sales of approximately  Read More »

June 14, 2012 Teva Announces Top-Line Results from GALA Phase III Trial Evaluating a New Dosage for Glatiramer Acetate Given Three Times Weekly for Relapsing-Remitting Multiple Sclerosis

The GALA study evaluating glatiramer acetate 40 mg/1 ml administered three times weekly met primary endpoint significantly reducing the annualized relapse rate (ARR) by 34.4 percent compared to placebo JERUSALEM--(BUSINESS WIRE)--Jun. 14, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced positive top-line results from the GALA (Glatiramer Acetate Low-Frequency Administration) Phase III clinical trial assessing the   Read More »

June 13, 2012 Teva Announces AZILECT® (Rasagiline Tablets) Data to Be Presented at the 16th Annual International Congress of Parkinson’s Disease and Movement Disorders

More Than 15 Clinical, Pre-Clinical and Health Economics Studies Will Be Presented JERUSALEM, Israel--(BUSINESS WIRE)--Jun. 13, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that data from studies of AZILECT® (rasagiline tablets) and Parkinson’s disease (PD) will be featured at the 16th Annual International Congress of Parkinson’s Disease and Movement Disorders in Dublin, Ireland, 17-21 June 2012.   Read More »

June 05, 2012 Teva to Present at the Jefferies 2012 Global Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Jun. 5, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Jefferies 2012 Global Healthcare Conference in New York. Jon Congleton, Senior Vice President, Global Brand Strategic Marketing, will present on Wednesday, June 6, 2012. What:   Teva Presentation at the Jefferies   Read More »

June 04, 2012 Teva to Present at the Goldman Sachs 33rd Annual Global Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Jun. 4, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Goldman Sachs 33rd Annual Global Healthcare Conference in California. Dr. Jeremy Levin, President & CEO, will present on Tuesday, June 5, 2012. What:   Teva Presentation at the Goldman Sachs 33rd  Read More »

June 01, 2012 Teva Pharmaceutical Industries Ltd. Chairman of the Board Dr. Phillip Frost Purchases 1 Million Teva Shares

JERUSALEM--(BUSINESS WIRE)--Jun. 1, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that Dr. Phillip Frost, Chairman of the Board of Directors, purchased one million Teva American Depositary Shares on Wednesday, May 30, 2012, the first day of trading on the New York Stock Exchange, at prices ranging from $37.82 to $39.57. Dr. Frost stated, "This investment is simply a reflection of the strength of my conviction regard  Read More »

May 30, 2012 Teva Begins Trading on the New York Stock Exchange

JERUSALEM--(BUSINESS WIRE)--May. 30, 2012-- Dr. Phillip Frost, Chairman of the Board of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), and Dr. Jeremy Levin, the Company’s President and CEO, along with a group of employees representing Teva’s businesses around the world, rang the Opening Bell at the New York Stock Exchange to celebrate the Company’s transfer to the NYSE. The Company’s American Depositary Shares began trading this morning on the NYS  Read More »

May 30, 2012 Teva to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference

JERUSALEM--(BUSINESS WIRE)--May. 30, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Sanford C. Bernstein Twenty-Eighth Annual Strategic Decisions Conference in New York. Dr. Jeremy Levin, President and CEO, will present on today, May 30, 2012 at 2:00 PM ET. What:   Teva Presentation at the Sanford C. Bernstein 28th Annua  Read More »

May 24, 2012 Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40

JERUSALEM--(BUSINESS WIRE)--May. 24, 2012-- On its conference call today, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) provided its current outlook for non-GAAP financial performance for the full year ending December 31, 2012. This outlook is summarized below. Total net sales of approximately $20-$21 billion, consisting of total U.S. net sales of $10.5 billion, total European net sales of $5.8 billion, and total ROW  Read More »

May 23, 2012 Teva to Host Conference Call and Webcast on May 24, 2012

JERUSALEM--(BUSINESS WIRE)--May. 23, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the Company's President and Chief Executive Officer Dr. Jeremy Levin will host a conference call and webcast to discuss his recent transition to CEO, and provide an update on financial guidance for 2012 and general business on Thursday, May 24, 2012 at 8:00 a.m. Eastern Time. A live webcast of the call will be available on Teva's website at: http://www.tevapharm.com. Please log i  Read More »

May 17, 2012 Teva’s Board of Directors Votes to Re-Elect Dr. Phillip Frost as Chairman of the Board

JERUSALEM--(BUSINESS WIRE)--May. 17, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that its Board of Directors has unanimously voted to re-elect Dr. Phillip Frost as Chairman of the Board for a term of three years. Dr. Frost’s re-election as a director is subject to shareholder approval at the upcoming annual meeting of shareholders. Commenting on the Board’s decision, Professor Moshe Many, Vice Chairman of   Read More »

May 09, 2012 Teva Issues Updated Conference Call Information for First Quarter 2012 Financial Results on May 9, 2012

JERUSALEM--(BUSINESS WIRE)--May. 9, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today issued updated dial-in information regarding the conference call to be held today, May 9, 2012 at 8:30 a.m. ET to discuss its first quarter 2012 results. The call will be webcast and can be accessed through the Company's website at www.tevapharm.com, or by dialling in to 866.652.8972 or 800.994.4498 (U.S.), 0.800.032.3367 (UK), or 972.3.  Read More »

May 09, 2012 Teva Reports First Quarter 2012 Results

Net Revenues Total $5.1 Billion, up 25% Non-GAAP EPS of $1.47, up 41% JERUSALEM--(BUSINESS WIRE)--May. 9, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today reported results for the quarter ended March 31, 2012. Highlights: Net revenues of $5.1 billion, compared to $4.1 billion in the first quarter of 2011, an increase of 25%. Non-GAAP operating income of $1.6 billion, an increase of 42% compared to $1.1 billion in the first quarter of 2011. Non-GAAP net income and Non  Read More »

May 08, 2012 Teva Appoints Michael Hayden as President of Global Research and Development and Chief Scientific Officer

JERUSALEM--(BUSINESS WIRE)--May. 8, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that Dr. Michael R. Hayden, will join the company as the President of Global Research and Development and Chief Scientific Officer, based in Israel. In this new role, Dr. Hayden will lead all research and development for Teva, thus combining the efforts of two world-class teams focused on the development of both brand and generic medicines.   Read More »

April 30, 2012 Teva settles Nuvigil litigation with Mylan

JERUSALEM--(BUSINESS WIRE)--Apr. 30, 2012-- Teva Pharmaceutical Industries Ltd. (TEVA), one of the world’s largest producers of pharmaceuticals, announces that it has settled patent infringement litigation regarding U.S. Patent Number 7,132,570 (the "'570 patent") with respect to Mylan Inc.'s ANDA for Teva’s wakefulness product NUVIGIL® (armodafinil) tablets. The settlement allows Mylan to begin selling generic versions of 50 mg, 150 mg, and 250 mg N  Read More »

April 26, 2012 Preliminary Data Suggest Spasticity May Be Reduced in Relapsing-Remitting Multiple Sclerosis Patients Who Transitioned to Teva's COPAXONE®

Early Study Findings Indicate Improvement in Muscle Stiffness, Pain and Discomfort and Ability to Walk Following Discontinuation of Interferon-beta Treatment and Transition to COPAXONE(R) Data Presented at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans, Louisiana JERUSALEM, Apr 26, 2012 (BUSINESS WIRE) --Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced   Read More »

April 20, 2012 Teva to Report First Quarter 2012 Financial Results on May 9, 2012

JERUSALEM, Apr 20, 2012 (BUSINESS WIRE) --Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its first quarter 2012 financial results on Wednesday, May 9, 2012. Teva will host a conference call and live webcast on the same day, at 8:30 a.m. ET to discuss its first quarter 2012 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial  Read More »

April 18, 2012 Teva Announces New Data on Central Nervous System Products to Be Presented at 2012 American Academy of Neurology Annual Meeting

Meeting to Feature Research in Multiple Sclerosis, Parkinson's Disease and Wake-Promoting Medicine JERUSALEM, Israel, Apr 18, 2012 (BUSINESS WIRE) --Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced new data from the Company's expanding central nervous system (CNS) portfolio will be featured at the 64th American Academy of Neurology (AAN) Annual Meeting in New Orleans, LA, April 21-28, 2012. Thirty abstracts will highlight data   Read More »

April 05, 2012 FDA Decides Teva is Sole First-to-File on Provigil®

JERUSALEM--(BUSINESS WIRE)--Apr. 5, 2012-- Teva Pharmaceutical Industries Ltd. announces that the FDA has decided that its wholly owned subsidiary, Teva Pharmaceuticals USA, is sole first-to-file for both Orange Book patents listed for Provigil® (modafinil) and therefore Teva’s ANDA alone is entitled to 180-day exclusivity. Cephalon launched generic Provigil® on March 29, 2012 and the FDA has also decided that such launch triggered the exclusivity.   Read More »

April 02, 2012 Teva Announces Launch of Generic Avapro® and Generic Avalide® in the United States; Awarded 180-Day Period of Marketing Exclusivity

JERUSALEM--(BUSINESS WIRE)--Apr. 2, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has commenced commercial launch of both Irbesartan and Irbesartan-Hydrochlorothiazide Tablets, the Company’s generic versions of Sanofi Aventis’ high blood pressure treatments, Avapro® and Avalide® Tablets. The brand products had annual sales of approximately $464 million and $124 million, respectively, in the United States, based on   Read More »

April 02, 2012 Teva Announces Pricing of EUR 1 Billion and CHF 450 Million of Senior Notes, and the Closing of a New JPY 100 Billion Unsecured Syndicated Facility

- Debut EUR and CHF-Denominated Issuance by Teva - - Debut Syndicated Facility for Teva in the Japanese Market - JERUSALEM--(BUSINESS WIRE)--Apr. 2, 2012-- Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) ("Teva") announced today that it successfully priced its debut EUR 1 billion and CHF 450 million debt offerings, and that it entered into a JPY 100 billion (approximately USD 1.2 billion) senior unsecured fixed-rate syndicated   Read More »

March 30, 2012 Teva Announces Launch of Authorized Generic of Provigil®

JERUSALEM--(BUSINESS WIRE)--Mar. 30, 2012-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announces the launch of the authorized generic of Provigil® (modafinil). Provigil® is marketed by Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. This product will continue to be manufactured under the brand product's new drug application at the same facility where it is currently produced. Shipping of the product has   Read More »

March 28, 2012 Teva Announces Launch of Generic Seroquel® in the United States

JERUSALEM--(BUSINESS WIRE)--Mar. 28, 2012-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has commenced commercial launch of Quetiapine Fumarate Tablets, the Company’s generic version of AstraZeneca’s schizophrenia treatment, Seroquel® Tablets. The brand product had annual sales of approximately $4.6 billion in the United States, based on IMS sales data. About Teva Teva Pharmaceutical Industries Ltd  Read More »

March 26, 2012 Teva Announces FDA Approval of QNASLTM (beclomethasone dipropionate), a New Nonaqueous Nasal Aerosol, for the Treatment of Allergic Rhinitis

New Treatment with “Dry” Mode of Delivery Seeks to Address Unmet Needs of Seasonal and Perennial Allergy Sufferers JERUSALEM--(BUSINESS WIRE)--Mar. 26, 2012-- Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved QNASLTM Nasal Aerosol, a new, “dry” nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years o  Read More »

March 21, 2012 Teva Pharmaceutical Industries Ltd. to Transfer Listing to NYSE

JERUSALEM--(BUSINESS WIRE)--Mar. 21, 2012-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it is transferring the listing of its American Depositary Shares ("ADSs"), each representing one ordinary share of Teva common stock, to the New York Stock Exchange (NYSE) from the NASDAQ Global Select Market (NASDAQ). The Company expects to begin trading on the NYSE on May 30, 2012 under its current stock symbol "TEVA", but will continue to trade on NASDAQ until the transfer takes  Read More »

March 15, 2012 Phase III Study of Teva's Oral Laquinimod Published in the New England Journal of Medicine Demonstrates Clinical Benefits for Multiple Sclerosis Patients

Phase III ALLEGRO study results showed laquinimod reduced the annual rate of relapses, slowed the progression of disability, and decreased brain tissue loss Laquinimod was associated with favorable safety and tolerability profile European Union (EU) regulatory submission planned in H2 2012 JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Mar. 15, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced the publication of results  Read More »

March 14, 2012 Teva Announces Launch of Generic Lexapro® in the United States; Awarded 180-Day Period of Marketing Exclusivity

JERUSALEM--(BUSINESS WIRE)--Mar. 14, 2012-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has commenced commercial launch of Escitalopram Oxalate Tablets, the Company’s generic version of Forest Laboratories’ depression and generalized anxiety disorder treatment, Lexapro® Tablets. The brand product had annual sales of approximately $2.9 billion in the United States, based on IMS sales data. As the first com  Read More »

March 12, 2012 Teva to Present at the Barclays Capital Global Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Mar. 12, 2012-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Barclays Capital Global Healthcare Conference in Miami. William Marth, President & CEO, Teva Pharmaceuticals - Americas, will present on Tuesday, March 13, 2012.   What:   Read More »

March 08, 2012 Teva and OncoGenex Announce Updates to Custirsen Development Program in Advanced Prostate Cancer

Second Phase 3 Trial Evaluating Survival Benefit of Custirsen Planned to Initiate in 2012 JERUSALEM & BOTHELL, Wash. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Mar. 8, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today an update on their development program for custirsen, a product candidate being evaluated in Phase 3 studies for castrate-resistant prostate cancer (CRPC). In a revised agreement between the two comp  Read More »

March 05, 2012 QNASLTM Phase III Data Indicate Investigational Therapy with New Mode of Delivery has Positive Safety and Effective Profile in Treatment of Seasonal and Perennial Allergic Rhinitis

Late Stage Data Demonstrated Long-Term Nasal Symptom Relief and Improvement in Quality of Life JERUSALEM--(BUSINESS WIRE)--Mar. 5, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced positive findings from four Phase III clinical studies that examined the efficacy and safety profile as well as impact on quality of life (QoL) of QNASLTM (beclomethasone dipropionate [BDP]) Nasal Aerosol. QNASLTM is a non-aqueous, “d  Read More »

March 02, 2012 Teva Announces Launch of Generic Prometrium® Capsules in the United States

JERUSALEM--(BUSINESS WIRE)--Mar. 2, 2012-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Progesterone Capsules, 100 & 200 mg, the AB-rated generic equivalent of Abbott Laboratories’ Prometrium® Capsules. The brand product had annual sales of approximately $197 million in the United States, based on IMS sales data. The product is indicated for the treatment of secondary amenorrhea due   Read More »

February 28, 2012 Teva to Present at the 2012 RBC Capital Markets' Global Healthcare Conference

JERUSALEM, Feb 28, 2012 (BUSINESS WIRE) --Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the 2012 RBC Capital Markets' Global Healthcare Conference in New York. Lesley Russell, SVP, R&D Global Branded Products, will present on Wednesday, February 29, 2012. What: Teva Presentation at the 2012 RBC Capital  Read More »

February 24, 2012 Teva to Present at the Citi 2012 Global Health Care Conference

JERUSALEM--(BUSINESS WIRE)--Feb. 24, 2012-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Citi 2012 Global Health Care Conference in New York. Lesley Russell Cooper, SVP, R&D Global Branded Products, will present on Monday, February 27, 2012.   What:   Read More »

February 15, 2012 Teva Reports Fourth Quarter and Full Year 2011 Results

Fourth Quarter Net Revenues Total $5.7 Billion, up 28%, with Non-GAAP EPS of $1.59, up 27% Full Year 2011 Net Revenues Total $18.3 Billion, up 14%, with Non-GAAP EPS of $4.97, up 9% 25% Increase in Quarterly Dividend to NIS 1.00 Per Share JERUSALEM--(BUSINESS WIRE)--Feb. 15, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today reported results for the quarter and year ended December 31, 2011. Q  Read More »

January 16, 2012 Teva to Report Fourth Quarter and Full Year 2011 Financial Results on February 15, 2012

JERUSALEM--(BUSINESS WIRE)--Jan. 16, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its fourth quarter and full year 2011 financial results on Wednesday, February 15, 2012. Teva will host a conference call and live webcast on the same day, at 8:30 a.m. ET to discuss its fourth quarter and full year 2011 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the  Read More »

January 09, 2012 Teva to Present at the 30th Annual J.P. Morgan Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Jan. 9, 2012-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the J.P. Morgan Healthcare Conference in San Francisco, CA. Eyal Desheh, Chief Financial Officer, and William Marth, President & CEO, Teva Pharmaceuticals - Americas, will present on Tuesday, January 10, 2012. What: Teva Presentation at the 30th Annual J.P. Morgan Healthcare Conference Who: Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries Ltd. &   Read More »

January 03, 2012 Advanced Magnetic Resonance Imaging Technology Suggests Axonal Repair in Multiple Sclerosis Patients Treated with COPAXONE®

Study Findings Published in Frontiers in Bioscience JERUSALEM, Jan 03, 2012 (BUSINESS WIRE) --Researchers utilizing an advanced magnetic resonance imaging (MRI) technology to characterize and chart the evolution of MS lesions found that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE® (glatiramer acetate injection) experienced significantly increased magnetization transfer ratio (MTR). Magnetization transfer ratio is a nonconventional MRI technique used to invest  Read More »

January 01, 2012 Teva Announces Management Succession

Dr. Jeremy Levin, A Former Senior Executive at Bristol-Myers Squibb, To Succeed Shlomo Yanai as President and CEO JERUSALEM--(BUSINESS WIRE)--Jan. 1, 2012-- Phillip Frost, MD, Chairman of the Board of Directors of Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA), announced today that Shlomo Yanai, President and CEO of Teva, plans to retire from the company effective May 2012, and that as part of a succession plan, the Board of Directors has named Dr. Jeremy Levin, a former senior executive at  Read More »

Previous | Next